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Abstract
Background: Hypomagnesemia is one of the characteristic side effects of the human anti-epidermal growth factor
receptor (EGFR) monoclonal antibodies, cetuximab and panitumumab.
The major mechanism of anti-EGFR antibody-related hypomagnesemia is suppression of EGFR-mediated urinary
Mg2+ reabsorption in both the renal tubule the intestinal tract.
Since Mg2+ is known to affect blood Ca2+ levels through regulation of parathyroid hormone (PTH) secretion, we
investigated the correlation between Ca2+ and Mg2+ concentration in blood.
Methods: Between April 2012 and October 2015, blood Mg2+ and Ca2+ concentrations (albumin corrected value) of
22 colon cancer patients undergoing treatment with either cetuximab or panitumumab at Toyooka Public Hospital
were measured simultaneously.
Results: Hypomagnesemia (of all Grades) was reported in 13 of 22 patients. Two patients had hypomagnesemia of
severity > Grade 3.
Changes in blood Mg2+ and Ca2+ concentration showed a significant correlation (r2 = 0.7455), which could be
expressed using the following equation, Ca2+ concentration = 1.4268 × (Mg2+ concentration) + 7.1126.
Conclusion: Since the early stages of hypomagnesemia produce no characteristic clinical symptoms, it is easily
overlooked until it becomes severe.
The investigation results suggest that if low blood Ca2+ concentration (mg/dL) is observed in patients administered
anti-EGFR antibodies, early evaluation of blood Mg2+ concentration (mg/dL) and prompt supportive care are
required to prevent aggravation of hypomagnesemia.
Keywords: Hypomagnesemia, Calcium, EGFR-targeting antibodies, Cetuximab, Panitumumab
Background
Cetuximab and panitumumab are anti-epidermal
growth factor receptor (EGFR) monoclonal antibodies.
Both antibodies are molecular-targeted drugs and their
efficacy has been indicated not only in primary treat-
ment, but also in secondary and tertiary treatment of
advanced or recurrent colorectal cancer not harboring
mutations in the KRAS gene [1].
Various side effects of molecular-targeted agents are
known, which are unlikely to occur with a conventional
cytotoxic agent. Some of the characteristic side effects
of anti-EGFR antibodies include infusion reaction, skin
symptoms such as acne-like rash, and electrolyte abnor-
malities. Of the electrolyte abnormalities, hypomagnes-
emia is a hidden side effect because it is asymptomatic
and progresses slowly despite its high frequency [2].
The causes include inhibition of EGFR-mediated Mg2+
re-absorption from urine in renal tubules, and inhibition
of EGFR-mediated Mg2+ absorption in the intestinal
tract [3].
* Correspondence: toshiyasu-tsujii@toyookahp-kumiai.or.jp
1Section of Clinical Pharmaceutics, Department of Clinical Pharmacy,
Graduate School of Pharmacy, Hyogo University of Health Sciences, 1-3-6,
Minatojima, Chuo-ku, Kobe, Hyogo 665-8530, Japan
2Department of Pharmacy, Toyooka Public Hospital, 1094, Tobera, Toyooka,
Hyogo 668-8501, Japan
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tsujii et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:23 
DOI 10.1186/s40780-016-0060-9
Furthermore, Mg2+ has been reported to affect blood
Ca2+ level [4] via its in vivo control of parathyroid hor-
mone (PTH) secretion.
Therefore, we examined the correlation between Ca2+
and Mg2+ concentration in patients’ blood.
Methods
Patients
The blood Mg2+ and Ca2+ concentrations (albumin cor-
rected value) of 22 colon cancer patients who received an
anti-EGFR antibody (either cetuximab or panitumumab)
at our hospital from April 2012 to October 2015 were
simultaneously measured. Fourteen of the 22 patients
were treated with cetuximab. The remaining 8 patients re-
ceived panitumumab (Table 1).
Procedures
Mg2+ and Ca2+ concentration in the blood was investigated
retrospectively using information from electronic medical
records. The severity of Mg2+ and Ca2+ concentration de-
cline (hypomagnesemia/hypocalcemia) was graded accord-
ing to Common Terminology Criteria for Adverse Events
ver4.0 (CTCAE ver4.0 Japanese translation JCOG version).
Magnesium oxide formulations are commonly used as
laxatives. Since they are expected to affect Mg2+ concen-
trations in blood, the incidence of hypomagnesemia was
studied for magnesium oxide co-treated and magnesium
oxide non-treated groups separately.
Skin toxicity is one of the characteristic side effects of hu-
man anti-EGFR monoclonal antibodies. Therefore, the rela-
tionship between hypomagnesemia and skin toxicity was
investigated. Skin toxicities included pruritus, acneiform
dermatitis, skin desquamation, exfoliative dermatitis, paro-
nychia, nail disorder, skin fissures, skin laceration, pruritic
rash, pustular rash, skin infection, and skin ulceration. Se-
lected skin toxicities were graded according to Common
Terminology Criteria for Adverse Events ver4.0 (CTCAE
ver4.0 Japanese translation JCOG version).
Differences in patient background between the hypo-
magnesemia groups and non-hypomagnesemia groups
were investigated.
Statistical analysis
Statistical analyses were performed by using the chi-square
test for categorical variables and Mann-Whitney’s U test for
order variables. The relationship between Mg2+ and Ca2+
concentration in blood was examined using a single regres-
sion analysis. Statistical analysis was performed using SPSS®
version 11. The significance level of the test was set at 5 %.
Ethical issues
This study was approved by the research ethics commit-
tee of Toyooka Public Hospital (No. 102) and was per-
formed according to the Declaration of Helsinki.
The waiver of informed consent from individual pa-
tients was approved by the ethics committee. Anon-
ymized data with serial study ID numbers created by the
study hospital were used throughout the study.
Results
Patients
Patient characteristics are shown in Table 1. Forty-three
patients were treated with anti-EGFR antibodies. Of
these, 21 patients were excluded from analysis owing to
lack of data on Mg2+ concentration or asynchronous
measurement of Ca2+ and Mg2+. Finally, 22 patients
were included (17 men and 5 women); the median age
was 65 years.
Mg2+ concentration before introducing an anti-
EGFR antibody was 2.13 ± 0.22 mg/dL. Eleven patients
received magnesium oxide co-treatment and the other
11 did not.
Investigation of incidence frequency
The incidence frequency of hypomagnesemia after the
start of anti-EGFR antibody administration was 59.1 %
(13 cases). About 18.2 % of the patients (4 cases) had
Grade 2 hypomagnesemia, and 9.1 % (2 cases) had
Grade 3 hypomagnesemia.
The incidence frequency of hypocalcemia after the
start of anti-EGFR antibody administration was 72.7 %
(16 cases), with 4.5 % of patients (1 case) having Grade 2
hypocalcemia, and none having hypocalcemia higher
than Grade3 (Table 2).
Correlation between Mg2+ and Ca2+ concentration in
blood
Statistical analyses were performed using single re-
gression analysis. The results show the trends and a
significant correlation (r2 = 0.7455) between serum Mg2+
concentration and serum Ca2+ concentration that fits the
following linear equation: Ca concentration = 1.4268 × (Mg
concentration + 7.1126) (Fig. 1).
Comparison of the incidence of hypomagnesemia in the
presence or absence of oral magnesium oxide co-
treatment
During treatment with anti-EGFR antibodies, 11 patients
were co-treated with oral magnesium oxide preparation
for constipation (group with co-treatment). The inci-
dence of Grade 1 or higher hypomagnesemia in this
group was 63.6 % (7 patients). The incidence in the mag-
nesium oxide non-treated group (11 patients) was
54.5 % (6 cases).
No significant difference in incidence of hypomagnes-
emia was observed between the magnesium oxide co-
treated group and the magnesium oxide non-treated group
(Fig. 2; p = 0.665 by χ2 test).
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Correlation between severity of skin toxicity and
hypomagnesemia
In anti-EGFR antibody-treated patients, the incidence of
Grade 0 or 1 skin toxicity was 40.9 % (9 patients) and
that of Grade 2 or higher skin toxicity was 59.0 % (13
patients). Magnesium values in each group were 1.80 ±
0.32, and 1.51 ± 0.60 mg/dL. No significant difference
was observed (p = 0.53; Table 3).
Comparison of patient characteristics in hypomagnesemia
No significant difference in patient characteristics was
observed between patients with and without hypomag-
nesemia (Table 4).
Discussion
In vivo, approximately 70 % of extracellular Mg2+ is
re-absorbed by the ascending limb of the loop of
Henle. The rest is re-absorbed in the proximal and
distal tubules. Since EGFR is frequently expressed on
the surface of the cells within the ascending limb of
the loop of Henle, anti-EGFR antibodies such as
cetuximab and panitumumab, inhibit EGFR in renal
tubular epithelial cells [5]. Consequently, the expres-
sion level of the Mg2+ channel, TRPM6 (transient
receptor potential member-6) decreases. Thus, Mg2+
transport decreases, resulting in Mg2+ loss in the kid-
ney, which is believed to underlie the pathogenesis of
hypomagnesemia [6, 7].
The intermediate aggregate results for a domestic
performance survey of the anti-EGFR antibody cetuxi-
mab showed that electrolyte abnormalities occurred
in 11.6 % patients (cases of Grade 3 or higher
Table 1 Patient characteristics
n = 22 Mean ± S.D. Median Range




Body Height (cm) 162.84 ± 8.35 163.35 149.00–175.30




































2.13 ± 0.22 2.00 1.80–2.60
Serum Calcium (mg/dL) 9.96 ± 0.33 9.85 9.50–10.50
Laboratory data
Neu (/mm3) 3716.8 ± 1459.1 3475.0 1380.0–6880.0
Table 1 Patient characteristics (Continued)
WBC (/mm3) 5936.3 ± 1685.9 5450.0 3200.0–10100.0
PLT (/mm3) 207,091 ± 5651 205,500 111,000–330,000
Hb (g/dl) 11.67 ± 1.73 11.55 7.80–14.4
sCre (mg/dl) 0.73 ± 0.31 0.64 0.51–1.88
AST (IU/l) 20.40 ± 4.44 21.00 12.00–28.00
ALT (IU/l) 15.40 ± 7.08 13.50 5.00–30.00
Patients treated with anti-EGFR antibodies = 43; serum Ca level was measured
for all patients
Table 2 Incidence of hypomagnesemia and hypocalcemia after





Any Grade 13 (59.1) 16 (72.7)
Grade 2 4 (18.2) 1 (4.5)
Grade 3/4 2 (9.1) 0 (0.0)
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abnormalities, 1.6 %; and severe cases, 0.2 %). Of the
total 1767 cases, 164 patients (9.3 %) had hypomag-
nesemia, 35 (2.0 %) had hypocalcemia, and 19 (1.1 %)
had hypokalemia.
The results of cetuximab post-marketing all-patient
surveillance as of July 2010 showed that among the 4345
total cases, 40 (0.9 %) exhibited decreased blood Mg2+,
which is considerably smaller than that observed in
Phase II clinical trials in Japan (51.3 %).
Since serum Mg2+ levels are not routinely measured at
many facilities, the ability to detect hypomagnesemia
may vary.
This varied capability can be considered a possible
reason for the frequency gap between these two reac-
tion reports. In vivo, Mg2+ participates in activation
of enzymes, peripheral nerve regulation of muscle re-
laxation, and bone formation. Mg2+ also plays a par-
ticularly important role as a cofactor required for the
catalytic activity of enzymes involved in intracellular
metabolism. Although mild Mg2+ decrease is usually
asymptomatic, as hypomagnesemia progresses, tetany,
tremors, seizures, muscle weakening and other neuro-
muscular symptoms, psychiatric symptoms, cardiovas-
cular symptoms such as severe arrhythmia, and other
y = 1.4268 x + 7.1126

















Fig. 1 Correlation between individual serum Mg level and serum Ca level. The solid line indicates the linear regression line
χ
Fig. 2 Oral magnesium oxide formulation administered to patients with hypomagnesemia during cetuximab and panitumumab treatment
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electrolyte abnormalities occur as complications [8].
Since hypomagnesemia is difficult to detect from sub-
jective symptoms in its early stages, few complaints
have been reported. Therefore, regular measurement
of serum Mg2+ level is needed.
In this study, the effect of administration of magnesium
oxide preparations in combination with an anti-EGFR
antibody was also analyzed. In the group administered
magnesium oxide preparations, although hypomagnes-
emia improvement occurred, no relation was observed
between magnesium oxide administration and hypomag-
nesemia improvement. Since oral magnesium oxide prep-
arations are only weakly absorbed in the intestinal tract
and are excreted by absorbing moisture from the intestine,
the lack of correlation could be attributed to its low oral
bioavailability.
In addition, skin toxicity such as acne-like rash and
paronychia with anti-EGFR antibody treatment, can
lead to early discontinuation of treatment. But Anti-
EGFR antibody drugs have been reported to have a
marked therapeutic effect in patients who exhibit skin
toxicities. Using the data in the present study, we inves-
tigated the correlation between skin toxicity and elec-
trolyte disturbances. We also looked for correlations
between patient characteristics and electrolyte distur-
bances, but were unable to discover a significant correl-
ation. Since all patients are routinely and thoroughly
screened for skin toxicity symptoms, we consider any
effect of skin toxicities on electrolyte imbalances (or
vice versa) to be slight.
Since an anti-EGFR antibody can now be used as the
primary treatment, cases of chronic administration are in-
creasing. Further, in cases where hypomagnesemia has been
reported, prolonged treatment with cetuximab is currently
required because of its marked therapeutic effect8). It has
been reported that in the elderly and in patients with high
pre-treatment serum Mg2+ levels, the risk of developing
hypomagnesemia is high, and the frequency of severe hypo-
magnesemia increases if anti-EGFR drug administration
exceeds 6 months [9]. Nakamoto et al. reported that since
recovery from severe hypomagnesemia is poor even if
supplemental Mg2+ is administered, withdrawal of anti-
EGFR antibodies was situationally required. To prevent
severe hypomagnesemia, prompt initiation of supportive
care should also be required [10].
Table 3 Correlation between the severity skin toxicity and
hypomagnesemia
Skin toxicity
Grade 0 ∙ 1 Grade 2< *p
No. (%) 9 (40.90) 13 (59.00)
Mg (mg/dl) Mean ± S.D. 1.80 ± 0.32 1.51 ± 0.60 0.53
*Mann-Whitney’s U test
Table 4 Subset analyses of hypomagnesemia
Hypomagnesemia
Grade 0 Grade 1< p
No 9 13
Sexa) Men/Women 6/3 11/2 0.316
Body Hight (cm)b) Mean ± S.D. 160.5 ± 9.6 164.4 ± 7.3 0.556
Body Weight (kg)b) Mean ± S.D. 57.3 ± 7.7 58.6 ± 10.2 0.647
PSa) 0/1or 2 6/3 7/6 0.439
AST (IU/l)b) Mean ± S.D. 20.1 ± 3.3 20.6 ± 5.1 0.794
ALT (IU/l)b) Mean ± S.D. 14.4 ± 7.3 16.0 ± 7.1 0.695
sCre (mg/dl)b) Mean ± S.D. 0.65 ± 0.10 0.79 ± 0.39 0.794
Neu (/mm3)b) Mean ± S.D. 3253 ± 907 4037 ± 1704 0.431
WBC (/mm3)b) Mean ± S.D. 5211 ± 1230 6438 ± 1815 0.144
PLT (/mm3)b) Mean ± S.D. 193,778 ± 43,260 216,308 ± 64,165 0.556
Hb (g/dl)b) Mean ± S.D. 11.83 ± 1.67 11.56 ± 1.83 0.948
Mg (mg/dl)b) Mean ± S.D. 2.14 ± 0.25 2.12 ± 0.21 0.749
Ca (mg/dl)b) Mean ± S.D. 10.00 ± 0.37 9.93 ± 0.32 0.845
Combination regimen FOLFIRI base 6 9
FOLFOX base 0 2
CPT-11 alone 2 0
Monotherapy 1 2
a)χ2test, b)Mann-Whitney’s U test
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Hypercalcemia has been reported in about 20–30 % of
cancer patients. In patients with malignant tumors, bone
destruction and tumor cell expansion associated with
bone metastasis lead to the production of PTH-related
peptides, which eventually result in the development of
hypercalcemia. Since onset is often sudden, blood Ca2+
concentration is regularly measured.
Hypercalcemia is typically associated with bone metas-
tasis. Although all patients were at stage IV, a significant
correlation between magnesium and calcium concentra-
tions in bone metastatic cancer patients was not ob-
served. ALP is a bone metastasis marker. A significant
difference in changes in ALP levels was not observed
between the hypercalcemia group and the non- hyper-
calcemia group (data not shown).
Ca2+ is a major regulator of PTH secretion, and Mg2+
regulates PTH secretion as well. Lack of intracellular Mg2+
is known to suppress PTH secretion, which may result in
reduction of serum PTH and Ca2+ levels. Therefore, in pa-
tients with hypomagnesemia due to administration of anti-
EGFR antibodies, hypocalcemia could be concurrent [4].
Since a correlation between Ca2+ and Mg2+ concentra-
tion in patients treated with an anti-EGFR antibody was
indicated in this investigation, it is suggested that prompt
evaluation of blood Mg2+ concentration is required to
avoid incidence of hypomagnesemia, especially when re-
duction in blood Ca2+ concentration is detected.
Conclusions
In conclusion, the investigation results suggest that if
low blood Ca2+ concentration (mg/dL) is observed in
patients administered anti-EGFR antibodies, early evalu-
ation of blood Mg2+ concentration (mg/dL) and prompt
supportive care are required to prevent aggravation of
hypomagnesemia. Changes in blood Mg2+ and Ca2+ con-
centration showed a significant correlation (r2 = 0.74555),
which could be expressed by the following equation: Ca2+
concentration = 1.4268 × (Mg concentration) + 7.1126.
Since there is no characteristic clinical symptom in early
stages of hypomagnesemia, it is easily overlooked until it
becomes severe. Since the correlation between Ca2+ and
Mg2+ concentration in patients treated with an anti-EGFR
antibody was indicated in this investigation, it is suggested
that prompt evaluation of blood Mg2+ concentration
is required to avoid an incidence of hypomagnesemia,
especially when reduction in blood Ca2+ concentra-
tion is detected.
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